Literature DB >> 32519778

Longitudinal Evaluation of Visual P300 Amplitude in Clinical High Risk Subjects: An ERP Study.

Naoya Oribe1,2,3, Yoji Hirano1,2, Elisabetta Del Re4,5, Raquelle I Mesholam-Gately6, Kristen A Woodberry6,7, Takefumi Ueno2,3, Shigenobu Kanba2,8, Toshiaki Onitsuka2, Martha E Shenton4, Kevin M Spencer1, Margaret A Niznikiewicz5.   

Abstract

AIM: We previously reported abnormal P300 and N200 in a visual oddball task, and progressive P300 amplitude reduction at one-year follow-up in patients with first episode schizophrenia. P300 reduction as well as intact P1/N1 were also observed in clinical high-risk subjects (CHR), but whether or not these components change over time is unknown. This study evaluates, longitudinally, the visual P300, as well as P1, N1, and N200, in CHR.
METHODS: Visual ERPs were recorded twice, once at baseline and once at one -year follow-up in CHR (n = 19) and healthy comparison subjects (HC; n = 28). Participants silently counted infrequent target stimuli ("x") among standard stimuli ("y") presented on the screen while the 64-channel electroencephalogram was recorded.
RESULTS: No CHR converted to psychosis from baseline to one-year follow-up in this study. Visual P300 amplitude was reduced and the latency was delayed significantly in CHR at both time points compared with HC. Furthermore, CHR subjects who had more positive symptoms showed more amplitude reduction at both time points. P1, N1 and N200 did not differ between groups.
CONCLUSION: Visual P300 amplitude was found to be reduced in CHR individuals compared with HC. We note that this finding is in subjects who did not convert to psychosis at one-year follow-up. The association between visual P300 amplitude and symptoms suggests that for CHR who often experience clinical symptoms and seek medical care, visual P300 may be an important index that reflects the pathophysiological impairment underlying such clinical states. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Entities:  

Keywords:  EEG; P300; clinical high risk; longitudinal; schizophrenia

Year:  2020        PMID: 32519778     DOI: 10.1111/pcn.13083

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  6 in total

Review 1.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

2.  Neurophysiological Face Processing Deficits in Patients With Chronic Schizophrenia: An MEG Study.

Authors:  Naotoshi Ohara; Yoji Hirano; Naoya Oribe; Shunsuke Tamura; Itta Nakamura; Shogo Hirano; Rikako Tsuchimoto; Takefumi Ueno; Osamu Togao; Akio Hiwatashi; Tomohiro Nakao; Toshiaki Onitsuka
Journal:  Front Psychiatry       Date:  2020-09-03       Impact factor: 4.157

3.  Long-Term Test-Retest Reliability of Auditory Gamma Oscillations Between Different Clinical EEG Systems.

Authors:  Yoji Hirano; Itta Nakamura; Shunsuke Tamura; Toshiaki Onitsuka
Journal:  Front Psychiatry       Date:  2020-09-02       Impact factor: 4.157

4.  Editorial: Current MEG Research in Psychiatry.

Authors:  Yoji Hirano; Peter J Uhlhaas
Journal:  Front Psychiatry       Date:  2021-02-02       Impact factor: 4.157

Review 5.  Trends in big data analyses by multicenter collaborative translational research in psychiatry.

Authors:  Toshiaki Onitsuka; Yoji Hirano; Kiyotaka Nemoto; Naoki Hashimoto; Itaru Kushima; Daisuke Koshiyama; Michihiko Koeda; Tsutomu Takahashi; Yoshihiro Noda; Junya Matsumoto; Kenichiro Miura; Takanobu Nakazawa; Takatoshi Hikida; Kiyoto Kasai; Norio Ozaki; Ryota Hashimoto
Journal:  Psychiatry Clin Neurosci       Date:  2022-01       Impact factor: 12.145

Review 6.  Neurophysiology in psychosis: The quest for disease biomarkers.

Authors:  Baihan Wang; Eirini Zartaloudi; Jennifer F Linden; Elvira Bramon
Journal:  Transl Psychiatry       Date:  2022-03-11       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.